{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:53:30Z","timestamp":1789458810192,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,23]]},"DOI":"10.7759\/cureus.72190","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T12:18:32Z","timestamp":1729685912000},"source":"Crossref","is-referenced-by-count":9,"title":["Ki-67 as a Marker to Differentiate Burkitt Lymphoma and Diffuse Large B-cell Lymphoma: A Literature Review"],"prefix":"10.7759","author":[{"given":"Nicyela J","family":"Harlendea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Harlendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdn201","article-title":"Burkitt lymphoma versus diffuse large B-cell lymphoma","volume":"19","author":"Rosenwald A","year":"2008","unstructured":"Rosenwald A, Ott G. Burkitt lymphoma versus diffuse large B-cell lymphoma. Ann Oncol. 2008, 19:iv67-9.","journal-title":"Ann Oncol"},{"key":"ref2","article-title":"","author":"Graham BS","year":"2023","unstructured":"Graham BS, Lynch DT. Burkitt Lymphoma. StatPearls Publishing, Treasure Island (FL); 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538148."},{"key":"ref3","article-title":"C-MYC rearrangements are frequent in aggressive mature B-Cell lymphoma with atypical morphology","volume":"1","author":"Zhao XF","year":"2008","unstructured":"Zhao XF, Hassan A, Perry A, Ning Y, Stass SA, Dehner LP. C-MYC rearrangements are frequent in aggressive mature B-Cell lymphoma with atypical morphology. Int J Clin Exp Pathol. 2008, 1:65-74.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13624","article-title":"Clinical and pathological features of Burkitt lymphoma showing expression of BCL2-an analysis including gene expression in formalin-fixed paraffin-embedded tissue","volume":"171","author":"Masqu\u00e9-Soler N","year":"2015","unstructured":"Masqu\u00e9-Soler N, Szczepanowski M, Kohler CW, et al.. Clinical and pathological features of Burkitt lymphoma showing expression of BCL2-an analysis including gene expression in formalin-fixed paraffin-embedded tissue. Br J Haematol. 2015, 171:501-8. 10.1111\/bjh.13624","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020343","article-title":"Comparison of Ki-67 labeling index patterns of diffuse large B-cell lymphomas and Burkitt lymphomas using image analysis: a multicenter study","volume":"11","author":"Chong Y","year":"2021","unstructured":"Chong Y, Kim TE, Cho U, et al.. Comparison of Ki-67 labeling index patterns of diffuse large B-cell lymphomas and Burkitt lymphomas using image analysis: a multicenter study. Diagnostics (Basel). 2021, 11:343. 10.3390\/diagnostics11020343","journal-title":"Diagnostics (Basel)"},{"key":"ref6","article-title":"Diffuse large B-cell lymphoma, NOS","author":"Gascoyne RD","year":"2017","unstructured":"Gascoyne RD, Campo E, Jaffe ES, et al.. Diffuse large B-cell lymphoma, NOS. WHO Classifications of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon, France; 2017. 330-4."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.18004619704","article-title":"A sarcoma involving the jaws in African children","volume":"46","author":"Burkitt D","year":"1958","unstructured":"Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958, 46:218-23. 10.1002\/bjs.18004619704","journal-title":"Br J Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-019-0733-7","article-title":"An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence","volume":"10","author":"Kalisz K","year":"2019","unstructured":"Kalisz K, Alessandrino F, Beck R, Smith D, Kikano E, Ramaiya NH, Tirumani SH. An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Insights Imaging. 2019, 10:56. 10.1186\/s13244-019-0733-7","journal-title":"Insights Imaging"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.24.7824","article-title":"Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells","volume":"79","author":"Dalla-Favera R","year":"1982","unstructured":"Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982, 79:7824-7. 10.1073\/pnas.79.24.7824","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34618","article-title":"Incidence of Burkitt lymphoma in the United States during 2000 to 2019","volume":"153","author":"Mburu W","year":"2023","unstructured":"Mburu W, Devesa SS, Check D, Shiels MS, Mbulaiteye SM. Incidence of Burkitt lymphoma in the United States during 2000 to 2019. Int J Cancer. 2023, 153:1182-91. 10.1002\/ijc.34618","journal-title":"Int J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al.. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022, 36:1720-48. 10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.21037\/aol-21-18","article-title":"Reframing Burkitt lymphoma: virology not epidemiology defines clinical variants","volume":"5","author":"Rochford R","year":"2021","unstructured":"Rochford R. Reframing Burkitt lymphoma: virology not epidemiology defines clinical variants. Ann Lymphoma. 2021, 5:10.21037\/aol-21-18","journal-title":"Ann Lymphoma"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/516047","article-title":"Burkitt lymphoma: pathogenesis and immune evasion","volume":"2010","author":"God JM","year":"2010","unstructured":"God JM, Haque A. Burkitt lymphoma: pathogenesis and immune evasion. J Oncol. 2010, 2010:10.1155\/2010\/516047","journal-title":"J Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034819","article-title":"Epidemiology and etiology of leukemia and lymphoma","volume":"10","author":"Bispo JA","year":"2020","unstructured":"Bispo JA, Pinheiro PS, Kobetz EK. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harb Perspect Med. 2020, 10:10.1101\/cshperspect.a034819","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2023.152182","article-title":"From the archives of MD Anderson Cancer Center: sporadic Burkitt lymphoma with a complex karyotype and SOX11 expression","volume":"66","author":"Siddiqui SH","year":"2023","unstructured":"Siddiqui SH, Thakral B, Aakash F, Ok CY, Tang Z, Medeiros LJ. From the archives of MD Anderson Cancer Center: sporadic Burkitt lymphoma with a complex karyotype and SOX11 expression. Ann Diagn Pathol. 2023, 66:152182. 10.1016\/j.anndiagpath.2023.152182","journal-title":"Ann Diagn Pathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0898-8","article-title":"Burkitt and Burkitt-like lymphomas: a systematic review","volume":"22","author":"Saleh K","year":"2020","unstructured":"Saleh K, Michot JM, Camara-Clayette V, Vassetsky Y, Ribrag V. Burkitt and Burkitt-like lymphomas: a systematic review. Curr Oncol Rep. 2020, 22:33. 10.1007\/s11912-020-0898-8","journal-title":"Curr Oncol Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-010-0076-4","article-title":"Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?","volume":"6","author":"Thomas DA","year":"2011","unstructured":"Thomas DA, O'Brien S, Faderl S, et al.. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?. Curr Hematol Malig Rep. 2011, 6:58-66. 10.1007\/s11899-010-0076-4","journal-title":"Curr Hematol Malig Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/AHMT.S94170","article-title":"Burkitt lymphoma in adolescents and young adults: management challenges","volume":"8","author":"Dozzo M","year":"2017","unstructured":"Dozzo M, Carobolante F, Donisi PM, et al.. Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther. 2017, 8:11-29. 10.2147\/AHMT.S94170","journal-title":"Adolesc Health Med Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004099","article-title":"The treatment of Burkitt lymphoma in adults","volume":"137","author":"Crombie J","year":"2021","unstructured":"Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults. Blood. 2021, 137:743-50. 10.1182\/blood.2019004099","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-020-00933-z","article-title":"Clinicopathological features of primary thyroid Burkitt's lymphoma: a systematic review and meta-analysis","volume":"15","author":"Hayashi T","year":"2020","unstructured":"Hayashi T, Hirokawa M, Kuma S, et al.. Clinicopathological features of primary thyroid Burkitt's lymphoma: a systematic review and meta-analysis. Diagn Pathol. 2020, 15:13. 10.1186\/s13000-020-00933-z","journal-title":"Diagn Pathol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8935-5_25","article-title":"An introduction to the performance of immunohistochemistry","volume":"1897","author":"Magaki S","year":"2019","unstructured":"Magaki S, Hojat SA, Wei B, So A, Yong WH. An introduction to the performance of immunohistochemistry. Methods Mol Biol. 2019, 1897:289-98. 10.1007\/978-1-4939-8935-5_25","journal-title":"Methods Mol Biol"},{"key":"ref22","article-title":"Burkitt lymphoma","author":"Leoncini L","year":"2017","unstructured":"Leoncini L, Campo E, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt lymphoma. WHO Classifications of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon, France; 2017. 291-7."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.20471\/acc.2019.58.02.25","article-title":"Burkitt lymphoma in gastrointestinal tract: a report of two cases","volume":"58","author":"\u010cubrani\u0107 A","year":"2019","unstructured":"\u010cubrani\u0107 A, Gol\u010di\u0107 M, Fu\u010dkar-\u010cupi\u0107 D, Brozovi\u0107 B, Gajski D, Brumini I. Burkitt lymphoma in gastrointestinal tract: a report of two cases. Acta Clin Croat. 2019, 58:386-90. 10.20471\/acc.2019.58.02.25","journal-title":"Acta Clin Croat"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae017","article-title":"The treatment of Burkitt lymphoma with the Berlin-Frankfurt-M\u00fcnster protocol with rituximab and consolidative autologous transplantation","volume":"29","author":"Broccoli A","year":"2024","unstructured":"Broccoli A, Argnani L, Gugliotta G, et al.. The treatment of Burkitt lymphoma with the Berlin-Frankfurt-M\u00fcnster protocol with rituximab and consolidative autologous transplantation. Oncologist. 2024, 29:e789-95. 10.1093\/oncolo\/oyae017","journal-title":"Oncologist"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S407804","article-title":"Refractory Burkitt lymphoma: diagnosis and interventional strategies","volume":"14","author":"Malfona F","year":"2024","unstructured":"Malfona F, Testi AM, Chiaretti S, Moleti ML. Refractory Burkitt lymphoma: diagnosis and interventional strategies. Blood Lymphat Cancer. 2024, 14:1-15. 10.2147\/BLCTT.S407804","journal-title":"Blood Lymphat Cancer"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdi403","article-title":"Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol","volume":"16","author":"Divin\u00e9 M","year":"2005","unstructured":"Divin\u00e9 M, Casassus P, Koscielny S, et al.. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol. 2005, 16:1928-35.","journal-title":"Ann Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.03.012","article-title":"Chemotherapy treatments for Burkitt lymphoma: systematic review of interventional studies","volume":"21","author":"Della Rocca AM","year":"2021","unstructured":"Della Rocca AM, Leonart LP, Ferreira VL, et al.. Chemotherapy treatments for Burkitt lymphoma: systematic review of interventional studies. Clin Lymphoma Myeloma Leuk. 2021, 21:514-25. 10.1016\/j.clml.2021.03.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3167-7","article-title":"Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens","volume":"97","author":"Oosten LE","year":"2018","unstructured":"Oosten LE, Chamuleau ME, Thielen FW, et al.. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Ann Hematol. 2018, 97:255-66. 10.1007\/s00277-017-3167-7","journal-title":"Ann Hematol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.715346","article-title":"Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma\/leukemia","volume":"54","author":"Kasamon YL","year":"2013","unstructured":"Kasamon YL, Brodsky RA, Borowitz MJ, et al.. Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma\/leukemia. Leuk Lymphoma. 2013, 54:483-90. 10.3109\/10428194.2012.715346","journal-title":"Leuk Lymphoma"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li S","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018, 50:74-87. 10.1016\/j.pathol.2017.09.006","journal-title":"Pathology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.5581\/1516-8484.20120111","article-title":"Pathophysiology and molecular aspects of diffuse large B-cell lymphoma","volume":"34","author":"Gouveia GR","year":"2012","unstructured":"Gouveia GR, Siqueira SA, Pereira J. Pathophysiology and molecular aspects of diffuse large B-cell lymphoma. Rev Bras Hematol Hemoter. 2012, 34:447-51. 10.5581\/1516-8484.20120111","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref32","doi-asserted-by":"crossref","DOI":"10.1053\/j.semdp.2011.04.001","article-title":"Molecular pathogenesis of diffuse large B-cell lymphoma","volume":"28","author":"Schneider C","year":"2011","unstructured":"Schneider C, Pasqualucci L, Dalla-Favera R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol. 2011, 28:167-77.","journal-title":"Semin Diagn Pathol"},{"key":"ref33","article-title":"Diffuse Large B-Cell Lymphoma","author":"Padala SA","year":"2023","unstructured":"Padala SA, Kallam A. Diffuse Large B-Cell Lymphoma. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4103\/jomfp.JOMFP_294_18","article-title":"Diffuse large B-cell lymphoma: an immunohistochemical approach to diagnosis","volume":"23","author":"Sethi A","year":"2019","unstructured":"Sethi A, Tandon A, Mishra H, Singh I. Diffuse large B-cell lymphoma: an immunohistochemical approach to diagnosis. J Oral Maxillofac Pathol. 2019, 23:284-8. 10.4103\/jomfp.JOMFP_294_18","journal-title":"J Oral Maxillofac Pathol"},{"key":"ref35","article-title":"Heterogeneity among diffuse large B-cell lymphoma: new entities in WHO classification, a first step in personalized therapy","volume":"60","author":"Rotaru I","year":"2019","unstructured":"Rotaru I, T\u01cenase AD, Nacea JG, P\u0103tra\u015fcu S, Olteanu OA, P\u0103tra\u015fcu AM. Heterogeneity among diffuse large B-cell lymphoma: new entities in WHO classification, a first step in personalized therapy. Rom J Morphol Embryol. 2019, 60:41-8.","journal-title":"Rom J Morphol Embryol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.5045\/br.2022.2022037","article-title":"Basic immunohistochemistry for lymphoma diagnosis","volume":"57","author":"Cho J","year":"2022","unstructured":"Cho J. Basic immunohistochemistry for lymphoma diagnosis. Blood Res. 2022, 57:55-61. 10.5045\/br.2022.2022037","journal-title":"Blood Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1108837","article-title":"Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms","volume":"13","author":"Mao X","year":"2023","unstructured":"Mao X, Li Y, Liu S, et al.. Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms. Front Oncol. 2023, 13:1108837. 10.3389\/fonc.2023.1108837","journal-title":"Front Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.31557\/APJCC.2022.7.1.71","article-title":"Cell of origin based on Hans\u2019 algorithm as prognostic factor in diffuse large B-cell lymphoma: a clinicopathologic and survival study","volume":"7","author":"Probowati W","year":"2022","unstructured":"Probowati W, Purwanto I, Anggorowati N, et al.. Cell of origin based on Hans\u2019 algorithm as prognostic factor in diffuse large B-cell lymphoma: a clinicopathologic and survival study. Asian Pac J Cancer Care. 2022, 7:71-8. 10.31557\/APJCC.2022.7.1.71","journal-title":"Asian Pac J Cancer Care"},{"key":"ref39","article-title":"The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma","volume":"58","author":"P\u01cetra\u015fcu A","year":"2017","unstructured":"P\u01cetra\u015fcu A, Rotaru I, Olar L, et al.. The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma. Rom J Morphol Embryol. 2017, 58:837-43.","journal-title":"Rom J Morphol Embryol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27075","article-title":"2024 Update: Advances in the risk stratification and management of large B-cell lymphoma","volume":"98","author":"Tavakkoli M","year":"2023","unstructured":"Tavakkoli M, Barta SK. 2024 Update: Advances in the risk stratification and management of large B-cell lymphoma. Am J Hematol. 2023, 98:1791-805. 10.1002\/ajh.27075","journal-title":"Am J Hematol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.4103\/ajm.ajm_81_20","article-title":"High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma","volume":"10","author":"Zaiem F","year":"2020","unstructured":"Zaiem F, Jerbi R, Albanyan O, Puccio J, Kafri Z, Yang J, Gabali AM. High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma. Avicenna J Med. 2020, 10:241-8. 10.4103\/ajm.ajm_81_20","journal-title":"Avicenna J Med"},{"key":"ref42","article-title":"Cancer Signaling: From Molecular Biology to Targeted Therapy","author":"Wagener C","year":"2017","unstructured":"Wagener C, Stocking C, Mu\u0308ller O. Cancer Signaling: From Molecular Biology to Targeted Therapy. Wiley-VCH Verlag GmbH &amp; Co, Weinheim, Germany; 2017."},{"key":"ref43","article-title":"The Molecular Biology of Cancer","author":"Khan M","year":"2006","unstructured":"Khan M, Pelengaris, S. The Molecular Biology of Cancer. Wiley-Blackwell, Hoboken (NJ); 2006."},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s00412-018-0659-8","article-title":"Ki-67: more than a proliferation marker","volume":"127","author":"Sun X","year":"2018","unstructured":"Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma. 2018, 127:175-86. 10.1007\/s00412-018-0659-8","journal-title":"Chromosoma"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-023-09755-3","article-title":"Diagnostic, prognostic, and predictive role of Ki67 proliferative index in neuroendocrine and endocrine neoplasms: past, present, and future","volume":"34","author":"La Rosa S","year":"2023","unstructured":"La Rosa S. Diagnostic, prognostic, and predictive role of Ki67 proliferative index in neuroendocrine and endocrine neoplasms: past, present, and future. Endocr Pathol. 2023, 34:79-97. 10.1007\/s12022-023-09755-3","journal-title":"Endocr Pathol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnci.2011.11.001","article-title":"Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions","volume":"23","author":"Hafez NH","year":"2011","unstructured":"Hafez NH, Tahoun NS. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions. J Egypt Natl Canc Inst. 2011, 23:155-62. 10.1016\/j.jnci.2011.11.001","journal-title":"J Egypt Natl Canc Inst"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2014.2914","article-title":"Ki67 is a promising molecular target in the diagnosis of cancer (review)","volume":"11","author":"Li LT","year":"2015","unstructured":"Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015, 11:1566-72. 10.3892\/mmr.2014.2914","journal-title":"Mol Med Rep"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"Scholzen T","year":"2000","unstructured":"Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000, 182:311-22. 10.1002\/(SICI)1097-4652(200003)182:3&lt;311::AID-JCP1&gt;3.0.CO;2-9","journal-title":"J Cell Physiol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.258932","article-title":"Physiological functions and roles in cancer of the proliferation marker Ki-67","volume":"135","author":"Andr\u00e9s-S\u00e1nchez N","year":"2022","unstructured":"Andr\u00e9s-S\u00e1nchez N, Fisher D, Krasinska L. Physiological functions and roles in cancer of the proliferation marker Ki-67. J Cell Sci. 2022, 135: jcs258932. 10.1242\/jcs.258932","journal-title":"J Cell Sci"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-020-00957-5","article-title":"Automated quantitative analysis of Ki-67 staining and HE images recognition and registration based on whole tissue sections in breast carcinoma","volume":"15","author":"Feng M","year":"2020","unstructured":"Feng M, Deng Y, Yang L, et al.. Automated quantitative analysis of Ki-67 staining and HE images recognition and registration based on whole tissue sections in breast carcinoma. Diagn Pathol. 2020, 15:65. 10.1186\/s13000-020-00957-5","journal-title":"Diagn Pathol"},{"key":"ref51","doi-asserted-by":"crossref","DOI":"10.1136\/jcp.55.6.467","article-title":"Comparison of Ki-67 equivalent antibodies","volume":"55","author":"Lindboe CF","year":"2002","unstructured":"Lindboe CF, Torp SH. Comparison of Ki-67 equivalent antibodies. J Clin Pathol. 2002, 55:467-71.","journal-title":"J Clin Pathol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-0884-02","article-title":"MIB-1 (KI-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma","volume":"10","author":"Ghanem MA","year":"2004","unstructured":"Ghanem MA, Van der Kwast TH, Sudaryo MK, et al.. MIB-1 (KI-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma. Clin Cancer Res. 2004, 10:591-7. 10.1158\/1078-0432.ccr-0884-02","journal-title":"Clin Cancer Res"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S135593","article-title":"The diagnostic and prognostic values of Ki-67\/MIB-1 expression in thyroid cancer: a meta-analysis with 6,051 cases","volume":"10","author":"Pan DH","year":"2017","unstructured":"Pan DH, Wen DY, Luo YH, Chen G, Yang H, Chen JQ, He Y. The diagnostic and prognostic values of Ki-67\/MIB-1 expression in thyroid cancer: a meta-analysis with 6,051 cases. Onco Targets Ther. 2017, 10:3261-76. 10.2147\/OTT.S135593","journal-title":"Onco Targets Ther"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57094-3","article-title":"The prognostic and predictive potential of Ki-67 in triple-negative breast cancer","volume":"10","author":"Zhu X","year":"2020","unstructured":"Zhu X, Chen L, Huang B, et al.. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020, 10:225. 10.1038\/s41598-019-57094-3","journal-title":"Sci Rep"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S326189","article-title":"Prognostic value of Ki-67 expression in advanced lung squamous cell carcinoma patients treated with chemotherapy","volume":"13","author":"Wang D","year":"2021","unstructured":"Wang D, Ye W, Shi Q. Prognostic value of Ki-67 expression in advanced lung squamous cell carcinoma patients treated with chemotherapy. Cancer Manag Res. 2021, 13:6429-36. 10.2147\/CMAR.S326189","journal-title":"Cancer Manag Res"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5324-y","article-title":"Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis","volume":"19","author":"Luo ZW","year":"2019","unstructured":"Luo ZW, Zhu MG, Zhang ZQ, Ye FJ, Huang WH, Luo XZ. Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis. BMC Cancer. 2019, 19:123. 10.1186\/s12885-019-5324-y","journal-title":"BMC Cancer"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.892807","article-title":"The prognostic role of Ki-67\/MIB-1 in cervical cancer: a systematic review with meta-analysis","volume":"21","author":"Pan D","year":"2015","unstructured":"Pan D, Wei K, Ling Y, Su S, Zhu M, Chen G. The prognostic role of Ki-67\/MIB-1 in cervical cancer: a systematic review with meta-analysis. Med Sci Monit. 2015, 21:882-9. 10.12659\/MSM.892807","journal-title":"Med Sci Monit"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7796.158507","article-title":"Significance of p53 and ki-67 expression in prostate cancer","volume":"7","author":"Verma R","year":"2015","unstructured":"Verma R, Gupta V, Singh J, et al.. Significance of p53 and ki-67 expression in prostate cancer. Urol Ann. 2015, 7:488-93. 10.4103\/0974-7796.158507","journal-title":"Urol Ann"},{"key":"ref59","article-title":"Ki67 is a prognostic marker for neuroendocrine tumors","volume":"25","author":"Yin Y","year":"2014","unstructured":"Yin Y, Yan C, Zhou Y, Qiu J, Guo R. Ki67 is a prognostic marker for neuroendocrine tumors. Ann Oncol. 2014, 25:iv403.","journal-title":"Ann Oncol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-153","article-title":"Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis","volume":"14","author":"He X","year":"2014","unstructured":"He X, Chen Z, Fu T, et al.. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer. 2014, 14:153. 10.1186\/1471-2407-14-153","journal-title":"BMC Cancer"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2016.01.01","article-title":"Immunohistochemistry and scoring of Ki-67 proliferative index and p53 expression in gastric B cell lymphoma from Northern African population: a pilot study","volume":"7","author":"Zeggai S","year":"2016","unstructured":"Zeggai S, Harir N, Tou A, Sellam F, Mrabent MN, Salah R. Immunohistochemistry and scoring of Ki-67 proliferative index and p53 expression in gastric B cell lymphoma from Northern African population: a pilot study. J Gastrointest Oncol. 2016, 7:462-8. 10.21037\/jgo.2016.01.01","journal-title":"J Gastrointest Oncol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13172775","article-title":"Comparison of Ki67 proliferation index in gastrointestinal non-Hodgkin large B-cell lymphomas: the conventional method of evaluation or AI evaluation?","volume":"13","author":"Cristian M","year":"2023","unstructured":"Cristian M, A\u0219chie M, Deacu M, et al.. Comparison of Ki67 proliferation index in gastrointestinal non-Hodgkin large B-cell lymphomas: the conventional method of evaluation or AI evaluation?. Diagnostics (Basel). 2023, 13:2775. 10.3390\/diagnostics13172775","journal-title":"Diagnostics (Basel)"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.20075","article-title":"Classifying B-cell non-Hodgkin lymphoma by using MIB-1 proliferative index in fine-needle aspirates","volume":"118","author":"Ali AE","year":"2010","unstructured":"Ali AE, Morgen EK, Geddie WR, Boerner SL, Massey C, Bailey DJ, da Cunha Santos G. Classifying B-cell non-Hodgkin lymphoma by using MIB-1 proliferative index in fine-needle aspirates. Cancer Cytopathol. 2010, 118:166-72. 10.1002\/cncy.20075","journal-title":"Cancer Cytopathol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21406","article-title":"Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma","volume":"84","author":"Broyde A","year":"2009","unstructured":"Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol. 2009, 84:338-43. 10.1002\/ajh.21406","journal-title":"Am J Hematol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3389\/fnume.2022.829138","article-title":"Ki67 immunohistochemical expression level \u226570%, bulky presentation \u22657.5 cm, meningeal lymphomatosis, and interim PET \u0394SUVmax after 4 treatment cycles <71% as parts of a practical scoring system to predict progression-free survival and overall survival in diffuse large B-cell lymphoma","volume":"2","author":"Rebi\u00e8re V","year":"2022","unstructured":"Rebi\u00e8re V, Maajem M, Le Calloch R, et al.. Ki67 immunohistochemical expression level \u226570%, bulky presentation \u22657.5 cm, meningeal lymphomatosis, and interim PET \u0394SUVmax after 4 treatment cycles &lt;71% as parts of a practical scoring system to predict progression-free survival and overall survival in diffuse large B-cell lymphoma. Front Nucl Med. 2022, 2:829138. 10.3389\/fnume.2022.829138","journal-title":"Front Nucl Med"},{"key":"ref66","article-title":"Ki-67 proliferative index in the non-Hodgkin\u2019s lymphoma and its clinical significance","volume":"13","author":"Mudassar M","year":"2019","unstructured":"Mudassar M, Hameed S, Aslam S, Majeed R, Khan RU, Majee M. Ki-67 proliferative index in the non-Hodgkin\u2019s lymphoma and its clinical significance. Ann Punjab Med Coll. 2019, 13:","journal-title":"Ann Punjab Med Coll"},{"key":"ref67","article-title":"C-MYC protein expression and high Ki-67 proliferative index are predictives of disease relapse in diffuse large B cell lymphoma","volume":"6","author":"El-Hussien MT","year":"2021","unstructured":"El-Hussien MT, Mokhtar N, Khorshed EN. C-MYC protein expression and high Ki-67 proliferative index are predictives of disease relapse in diffuse large B cell lymphoma. Asian Pac J Cancer Biol. 2021, 6:15-20.","journal-title":"Asian Pac J Cancer Biol"},{"key":"ref68","article-title":"Association of Ki-67 proliferative index with clinico-pathological features of non-Hodgkin\u2019s lymphoma classified according to WHO (2008)","volume":"2","author":"Meena M","year":"2016","unstructured":"Meena M, Mehta J. Association of Ki-67 proliferative index with clinico-pathological features of non-Hodgkin\u2019s lymphoma classified according to WHO (2008). Int J Med Res Prof. 2016, 2:103-07.","journal-title":"Int J Med Res Prof"},{"key":"ref69","article-title":"Contribution of MYC FISH in pathological diagnosis of Burkitt lymphoma","volume":"11","author":"Poumsuk U","year":"2015","unstructured":"Poumsuk U, Chaichana T, Ruangvejvorachai P, et al.. Contribution of MYC FISH in pathological diagnosis of Burkitt lymphoma. AAJ. 2015, 11:50-6.","journal-title":"AAJ"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-671362","article-title":"MYC in DLBCL: partners matter","volume":"126","author":"Campo E","year":"2015","unstructured":"Campo E. MYC in DLBCL: partners matter. Blood. 2015, 126:2439-40. 10.1182\/blood-2015-10-671362","journal-title":"Blood"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/hon.916","article-title":"Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach","volume":"28","author":"Bellan C","year":"2010","unstructured":"Bellan C, Stefano L, Giulia de F, Rogena EA, Lorenzo L. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. Hematol Oncol. 2010, 28:53-6. 10.1002\/hon.916","journal-title":"Hematol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/296875-ki-67-as-a-marker-to-differentiate-burkitt-lymphoma-and-diffuse-large-b-cell-lymphoma-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T12:18:39Z","timestamp":1729685919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/296875-ki-67-as-a-marker-to-differentiate-burkitt-lymphoma-and-diffuse-large-b-cell-lymphoma-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":71,"URL":"https:\/\/doi.org\/10.7759\/cureus.72190","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}